Lyell Immunopharma, Inc. (LYEL) Financials

LYEL Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 350.6 million 77.0 million
Dec. 31, 2025 340.1 million 91.9 million
Sept. 30, 2025 408.0 million 78.8 million
June 30, 2025 385.5 million 86.5 million

LYEL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -38.6 million 4.3 million
Dec. 31, 2025 -32.6 million 25.6 million
Sept. 30, 2025 -28.6 million 5.2 million
June 30, 2025 -34.6 million 5.0 million

LYEL Net Income

No data available :(

LYEL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 254.0 million 39.5 million -
Dec. 31, 2025 247.2 million - 41.9 million
Sept. 30, 2025 319.6 million - 44.3 million
June 30, 2025 276.8 million - 55.1 million

LYEL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 21.9 million
Dec. 31, 2025 17.1 million
Sept. 30, 2025 18.3 million
June 30, 2025 14.8 million

LYEL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 89000 36.6 million 9.6 million -
Dec. 31, 2025 304000 52.2 million 10.6 million -
Sept. 30, 2025 62000 28.2 million 10.7 million -
June 30, 2025 168000 34.9 million 9.8 million -

LYEL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 2000 2.3 million
Dec. 31, 2025 6000 2.4 million
Sept. 30, 2025 15000 -
June 30, 2025 8000 3.1 million

LYEL Revenue by Segment
Graph available only for paid members. Upgrade to see it.

LYEL

Price: $12.44

52 week price:
8.46
45.00

Earnings Per Share: -13.62 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 208634

Market Capitalization: 279.3 million

Links: